1 / 21

RAJESH V. DUDHANI, JIAN LI, ROGER L. NATION

RAJESH V. DUDHANI, JIAN LI, ROGER L. NATION Facility for Anti-infective Drug Development & Innovation Drug Delivery, Disposition and Dynamics Monash Institute of Pharmaceutical Sciences ISAP Post-ICAAC Symposium, 15 September, 2009 San Francisco.

gauri
Download Presentation

RAJESH V. DUDHANI, JIAN LI, ROGER L. NATION

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. RAJESH V. DUDHANI, JIAN LI, ROGER L. NATION Facility for Anti-infective Drug Development & InnovationDrug Delivery, Disposition and Dynamics Monash Institute of Pharmaceutical Sciences ISAP Post-ICAAC Symposium, 15 September, 2009 San Francisco Concentration-dependent Plasma Binding of Colistin: Impacts of Infection, Neutropenia & Multiple Proteins

  2. Outline • Background • Methods • Results and Discussion • Conclusions

  3. Outline • Background • Methods • Results and Discussion • Conclusions

  4. The threat from the PINK corner Gram-negative ‘superbugs’: Acinetobacter baumannii Klebsiella pneumoniae Pseudomonas aeruginosa • Virtually NO antibiotics active against G-negatives in next 9 - 11 years • Currently, colistin often the only active antibiotic IDSA 2004, 2006, 2009 Livermore Ann Med 2003 Payne et al. Nat Rev Drug Discov 2007

  5. Colistin • Colistin (polymyxin E) • Antibacterial activity • Narrow spectrum: G-neg bacteria (P. aeruginosa, A. baumannii and K. pneumoniae) • Rapid bactericidal effect: Concentration-dependent • Very modest PAE against P. aeruginosa • Currently resistance is low, but emerging Li et al. Lancet Infect Dis 2006

  6. Colistin Colistin A: 6-methyloctanoic acid Colistin B: 6-methylheptanoic acid Dab: ,  -Diaminobutyric acid • multi-component • a weak organic base containing 5 primary amine groups • polycation at physiological pH Li et al. Lancet ID 2006

  7. 1 1 0 0 -1 -1 Killing Effect -2 -2 -3 -3 -4 -4 1.0 1.0 10.0 10.0 100.0 100.0 fAUC/MIC Colistin PK/PD index against P. aeruginosa in an in vitro dynamic model P. aeruginosa ATCC 27853 and PAO1 R2 = 81% R2 = 93% fCmax/MIC R2 = 70% 32.8 26.3 Bergen et al. submitted

  8. Higher plasma binding of polymyxin B in critically-ill patients 0.5 - 1.5 mg/kg every 12 or 48 h MICs Protein binding 78.5 - 92.4% vs56% in healthy human plasma Cao et al, JAC 2008 Zavascki et al, CID 2009

  9. Plasma binding of drugs • Crucial to understanding of PK/PD relationship • Two plasma proteins commonly involved • Human serum albumin (HSA): binds weak organic acids & bases and neutral compounds • alpha-1-acid glycoprotein (AAG) • the acute-phase reactant protein • often important for the binding of weak organic basic drugs • plasma concentrations of AAG (~0.75 g/L) are normally much lower than those of HSA (~45 g/L) • concentrations of AAG are increased (~3-5 fold) in a number of stressful conditions, including infection

  10. Aims • To investigate the proteins involved in the plasma binding of colistin • To examine the potential impact of colistin concentration on its plasma binding

  11. Outline • Background • Methods • Results and Discussion • Conclusions

  12. Methods • Healthy human plasma (Australian Red Cross) • Mouse plasma • Six-week old, female Swiss albino mice (22 - 26 g) were rendered neutropenic by IP cyclophosphamide (150 mg/kg) 4 days and (100 mg/kg) 1 day prior to experimental infection • Neutropenic mice were anesthetized and 50 µL early log-phase P. aeruginosa ATCC 27853 (~107 CFU) was injected into each posterior thigh • At 6 h, animals were humanely sacrificed & plasma was obtained

  13. Methods • Purified protein solutions in isotonic phosphate buffer (pH 7.4) • HSA: 22.5 g/L & 45 g/L • AAG: 0.75 g/L & 3 g/L • AAG/HSA: 0.75 g/L / 45 g/L; 3 g/L / 45 g/L • Equilibrium dialysis • Spectra Por 2® dialysis membrane (MW cut off 12,000 - 14,000) • Colistin-spiked plasma or solutions of purified protein(s) were dialyzed at 37ºC for 21 h • Initial colistin conc: 3 mg/L (low) & 30 mg/L (high) • In neutropenic infected mouse plasma, initial colistin conc 2.5 – 75 mg/L

  14. Methods • Colistin concentrations in the protein and buffer solutions were determined using a validated HPLC assay • The unbound fraction (fu) of colistin was calculated from the ratio, at dialysis equilibrium, of concentration in buffer to that in the protein-containing solution

  15. Outline • Background • Methods • Results and Discussion • Conclusions

  16. Plasma binding of colistin: proteins involved • Concentration dependent • AAG and HSA • Healthy human plasma vs physiological concentrations of HSA/AAG HSA 22.5 g/L Human plasma Low colistin concentrations: 0.81 - 1.71 mg/L High colistin concentrations: 5.69 - 11.1 mg/L AAG 0.75 g/L HSA 45 g/L AAG 3 g/L HSA 45g/L AAG 0.75 g/L HSA 45 g/L AAG 3 g/L

  17. Plasma binding of colistin in mice • fu in healthy mouse plasma is similar to that in healthy human plasma • fu in neutropenic and neutropenic infected mouse plasma are lower Mouse plasma Neutropenic mouse plasma Neutropenic infected mouse plasma Low concentrations: 1.42 - 1.80 mg/L High concentrations: 12.9 - 14.9 mg/L

  18. Conc-dependent plasma binding of colistin in mice Neutropenic infected mouse plasma • Colistin concentration range • (~0.9 – 30 mg/L) • fu increased ~4-5 fold as plasma concentration increased Dudhani et al. A1-576

  19. Outline • Background • Methods • Results and Discussion • Conclusions

  20. Conclusions • Both HSA and AAG are important in the binding of colistin in plasma • AAG conc increases in infections increased plasma binding of colistin • Colistin binding was dependent upon its concentration • Similar fAUC/MIC values from in vitro PK/PD model and mouse thigh infection model • Assist in defining optimal dosage regimens for colistin • Further investigation on colistin binding affinity, capacity to plasma proteins and bacterial cells is warranted

  21. Acknowledgements • FADDI team • NIH/NIAID R01AI079330 and R01AI070896 • Australian National Health & Medical Research Council

More Related